Aortitis surgery
|
Aortitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Aortitis surgery On the Web |
|
American Roentgen Ray Society Images of Aortitis surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]; Associate Editor(s)-In-Chief: Hibatullah Abdul Aleem, M.B.B.S[3]
Overview
Surgical and endovascular management of aortitis encompasses two fundamentally distinct clinical entities: non-infectious aortitis (large vessel vasculitis, isolated aortitis, IgG4-related disease) and infectious aortitis (mycotic aneurysm). The two share some procedural principles but differ critically in timing, conduit selection, perioperative adjunctive therapy, and postoperative surveillance requirements. Unlike atherosclerotic aortic disease, surgical decision-making in aortitis must account for ongoing or relapsing inflammation, the risk of anastomotic pseudoaneurysm in inflamed tissue, the need for perioperative immunosuppression or prolonged antimicrobial therapy, and the high rate of new vascular lesions requiring reintervention at remote sites. Medical therapy for aortitis is covered in the Medical Therapy microchapter.
Non-Infectious Aortitis
Indications for Surgical Intervention
Surgical or endovascular intervention in non-infectious aortitis is indicated for:[1][2]
- Aortic aneurysm at or approaching standard diameter thresholds for repair.
- Symptomatic aneurysm (pain, compression of adjacent structures, aortic regurgitation requiring valve intervention)
- Aortic dissection or rupture (emergency indication regardless of disease activity)
- Critical stenosis causing end-organ ischemia refractory to medical therapy (renovascular hypertension, cerebral ischemia from carotid or vertebral involvement, coronary artery involvement with symptomatic ischemia)
- Disabling limb claudication significantly impairing activities (note: the 2021 ACR/VF Guideline conditionally recommends against surgery for limb claudication alone in Takayasu arteritis, given the potential for collateral circulation to develop)
The diameter criteria for repair of asymptomatic inflammatory thoracic or abdominal aortic aneurysms follow the same thresholds as for non-inflammatory disease:[1]
- Ascending aorta or aortic root: ≥5.5 cm (Class I, LOE B-NR); ≥5.0 cm is reasonable at experienced centers (Class IIa, LOE B-NR)
- Descending thoracic aorta: ≥5.5 cm (Class I).
- Abdominal aorta: ≥5.5 cm in men, ≥5.0 cm in women.
Important caveat: Emerging data from cohorts of giant cell arteritis (GCA)-related aortitis suggest that inflammatory aneurysms may dissect at smaller aortic diameters than atherosclerotic aneurysms, though standard thresholds remain the formal recommendation pending further validation.[3] Rapid growth (≥0.5 cm/year or ≥0.3 cm/year in 2 consecutive years) is an additional indication for intervention regardless of absolute diameter.[1]
Timing of Surgery Relative to Disease Activity
Elective surgery should be performed during disease remission whenever possible. This is the single most important modifiable factor for reducing postoperative complications in non-infectious aortitis:[2][4]
- Studies in Takayasu arteritis demonstrate a higher rate of restenosis after endovascular therapy and a higher rate of anastomotic aneurysm formation and mortality after open surgery when performed during active disease.
- The 2021 ACR/VF Guideline conditionally recommends delaying surgical intervention until disease is quiescent.[2]
- When surgery cannot be delayed (rupture, dissection, impending organ infarction), perioperative immunosuppressive therapy is essential.
The 2021 ACR/VF Guideline conditionally recommends high-dose glucocorticoids during the periprocedural period for patients with active disease undergoing vascular surgery for both Takayasu arteritis and GCA.[2] The type and timing of intervention should be a collaborative decision between the vascular surgeon and the treating rheumatologist.
Surgical Approach: Open Versus Endovascular
Both open surgical and endovascular repair have been successfully employed in all types of inflammatory aortitis; the choice depends on anatomic site, patient age and comorbidities, disease activity, and institutional expertise.[4]
Open surgical repair remains the standard for most thoracic aortic aneurysms in inflammatory aortitis.[5]
TEVAR is a less invasive alternative for descending thoracic inflammatory disease when inflammation is properly managed. EVAR is recommended as first-line for infrarenal inflammatory aneurysms with appropriate anatomy.[1] Endovascular repair in actively inflamed aorta carries risks of endoleak, migration, and device-related complications, and long-term durability data remain limited.
Percutaneous intervention for stenotic lesions in Takayasu arteritis: A meta-analysis of 770 patients (389 endovascular, 420 open surgery) found restenosis significantly more common with endovascular than open surgical repair (OR 5.18; 95% CI 2.78–9.62); restenosis after endovascular therapy occurs more frequently than occlusion of surgical bypass grafts (43% vs. 17%).[6]
Postoperative Outcomes and Surveillance
A multicenter study of 217 patients with non-infectious surgical thoracic aortitis (Espitia et al., JACC 2023) demonstrated:[3]
- Non-infectious aortitis accounted for 3.8% of thoracic aortic surgeries; 30-day postoperative mortality was 7.3%.
- Aortic arch involvement doubled the risk of subsequent vascular complications (adjusted cause-specific hazard ratio 2.07).
- Descending aortic involvement and initial presentation with dissection (rather than aneurysm) were significant risk factors for requiring a second vascular procedure.
- Statin use after aortitis diagnosis reduced the likelihood of a second vascular surgery by more than half.
A subsequent histopathologic analysis found that the granulomatous or giant cell pattern was independently associated with higher 10-year mortality (HR 4.71 vs. lymphoplasmacytic pattern; P = 0.023), and aortic dissection at initial diagnosis was also independently associated with higher mortality (HR 6.07 vs. aneurysm at presentation).[7]
Postoperative complications specific to inflammatory aortitis include anastomotic pseudoaneurysm, aortoenteric fistula, hydroureteronephrosis (in IgG4-related periaortic fibrosis), perianeurysmal inflammation that does not fully resolve postoperatively, and new vascular lesions at remote sites. All patients require lifelong imaging surveillance (CTA or MRA) with close monitoring of disease activity by clinical symptoms, serologies, and imaging.[8]
Infectious Aortitis (Mycotic Aneurysm)
General Principles
Infectious aortitis carries high mortality from sepsis, aneurysm formation (saccular or pseudoaneurysm), erosion, fistula formation, dissection, and rupture.[1] The term "infectious aortitis" is now preferred over the older term "mycotic aneurysm," which incorrectly implies a fungal etiology. Management requires a combination of prolonged antimicrobial therapy and surgical or endovascular intervention in nearly all patients; medical treatment alone carries very high short-term mortality (37.5% at 30 days in one series) and should be reserved only for truly inoperable patients.[9]
Surgical Techniques
In situ reconstruction is the procedure of choice for most patients with infectious aortitis:[10]
- More versatile than extra-anatomic reconstruction; technically feasible for thoracic, suprarenal, infrarenal, and visceral locations.
- Associated with fewer long-term complications, higher patency rates, lower recurrent infection rate, and shorter operating time than extra-anatomic bypass.
- The operative bed should be meticulously debrided and the in situ graft wrapped with omentum, muscle flaps, or pleura.
Extra-anatomic reconstruction may be considered for selected patients with infrarenal infectious aortitis in the following circumstances:[10]
- Gross purulence in the intraoperative field.
- Retroperitoneal or psoas abscess.
- Adjacent vertebral osteomyelitis.
- Inadequate response to preoperative antimicrobial therapy.
- Selected aortoenteric fistulae.
Extra-anatomic reconstruction is generally not technically feasible for thoracic, suprarenal, or visceral locations, or in patients with rupture. Disadvantages include stump disruption (8–19%), limb amputation (17–27%), and reinfection (8–22%).[10]
TEVAR/EVAR serves primarily as a bridge procedure for emergency stabilization. In a multicenter series, endovascular treatment yielded 30-day survival of 91.7% but 3-year survival of only 20.8%, compared with 84% and 60.6% for radical open surgery, reflecting the poor long-term durability of endovascular repair alone in infectious aortitis.[9]
Conduit Selection for In Situ Reconstruction
No conduit has proven definitively superior; choice should be individualized based on anatomy, causative organism, availability, and institutional experience.[10][11]
| Conduit | Key Properties | Outcome Data |
|---|---|---|
| Rifampin-soaked Dacron graft | Readily available; rifampin active against gram-positive cocci including MRSA; suitable for emergency use | Higher freedom from graft-related reintervention at 5 years (92.5%) vs. cryopreserved allograft (66.2%; P = 0.02)[11] |
| Cryopreserved arterial allograft (CAA) | Resistant to infection; may contain branch vessels useful for concomitant renal or mesenteric bypass | Higher reintervention rates due to stenosis, pseudoaneurysm, and occlusion; similar 30-day mortality and 5-year survival vs. rifampin-soaked Dacron[11] |
| Silver-impregnated Dacron graft | May be combined with rifampin soaking for additive antimicrobial effect | Limited comparative outcome data |
| Autogenous deep vein (NAIS) | Created from femoropopliteal vein; lowest theoretical infection risk | Technically demanding; limited availability in the emergency setting |
| Bovine pericardial tubular xenograft | Used in select centers for radical infectious aortitis surgery | Limited comparative outcome data |
Surgical Outcomes
Overall outcomes for infectious aortitis remain poor despite modern management:[9]
- 30-day survival: 78.7%
- 1-year survival: 52.4%
- 3-year survival: 44.4%
- Radical open surgery yields the best long-term outcomes (3-year survival 60.6%)
- Endovascular treatment alone has poor long-term durability (3-year survival 20.8%)
- Medical treatment alone carries near-universal mortality at 3 years
2022 ACC/AHA Guideline Recommendations for Aortitis Surgery
Infectious Aortitis
| Class I |
| 1. In patients with infectious aortitis and associated aneurysms or dissection of the thoracic or abdominal aorta, open surgical repair is recommended. (Level of Evidence: C-EO)[1] |
| Class IIa |
| 2. In patients with infectious aortitis complicated by rupture, either open or endovascular repair is reasonable, based on the patient's status at presentation and institutional expertise. (Level of Evidence: C-EO)[1] |
| Class IIb |
| 3. In select patients with infectious aortitis and associated aneurysms or dissection, endovascular repair may be considered. (Level of Evidence: C-LD) 4. In patients with infectious aortitis, intravenous antimicrobial therapy of at least 6 weeks' duration may be considered, with lifelong suppressive therapy in select cases not amenable to interventional repair or who have recurrent infection. (Level of Evidence: C-EO)[1] |
Non-Infectious Aortitis: Aneurysm Size Thresholds
The 2022 ACC/AHA Guideline does not provide separate size thresholds for non-infectious inflammatory aortitis. Standard aneurysm diameter thresholds apply. The guideline notes that mycotic aneurysms and connective tissue disorders may justify intervention at smaller diameters, and the treating team should maintain a lower threshold in the setting of rapid growth, symptoms, GCA-related disease, or other high-risk features.[1]
2021 ACR/Vasculitis Foundation Guideline: Surgical Recommendations
Takayasu Arteritis
| 1. For patients with Takayasu arteritis and persistent limb claudication without active disease, surgical intervention is not recommended; collateral circulation may develop with ongoing immunosuppressive therapy.
2. For patients with Takayasu arteritis and worsening limb or organ ischemia while on immunosuppressive therapy, escalation of immunosuppressive therapy is preferred over surgical intervention. 3. For patients with Takayasu arteritis and renovascular hypertension with renal artery stenosis, medical management is preferred over surgery; surgical intervention is warranted for hypertension refractory to medical management or worsening renal function. 4. For patients with Takayasu arteritis and asymptomatic cranial or cervical vessel stenosis, medical management is preferred over surgical intervention. 5. For patients with Takayasu arteritis and active disease requiring surgery, high-dose glucocorticoids are recommended during the periprocedural period; elective surgery should be delayed until disease is quiescent when possible. (Conditional Recommendation*; Low Certainty of Evidence)[2] |
*A conditional recommendation indicates that the desirable effects of following the recommendation probably outweigh the undesirable effects, but the panel is not confident in these tradeoffs, either because the certainty of evidence is low or because patients' values and preferences vary.
Giant Cell Arteritis
| 1. For patients with giant cell arteritis and worsening limb or organ ischemia while on immunosuppressive therapy, escalation of immunosuppressive therapy is preferred over surgical intervention.
2. For patients with giant cell arteritis and aortic aneurysm at high risk for rupture or impending tissue or organ infarction, immediate surgical intervention should be considered. 3. For patients with giant cell arteritis and active disease at the time of vascular surgery, high-dose glucocorticoids are recommended during the periprocedural period; the type and timing of intervention should be a collaborative decision between the vascular surgeon and rheumatologist. (Conditional Recommendation*; Low Certainty of Evidence)[2] |
*A conditional recommendation indicates that the desirable effects of following the recommendation probably outweigh the undesirable effects, but the panel is not confident in these tradeoffs, either because the certainty of evidence is low or because patients' values and preferences vary.
Clinical Pearls
- Timing is paramount: Elective surgery during disease remission is the single most important modifiable factor for reducing complications in non-infectious aortitis; surgery during active inflammation is associated with higher restenosis rates, anastomotic pseudoaneurysm formation, and mortality.
- Multidisciplinary team is mandatory: All aortitis surgery decisions should involve rheumatology, vascular or cardiac surgery, and for infectious aortitis it should involve infectious diseases.
- In situ reconstruction is preferred over extra-anatomic bypass for most infectious aortitis; extra-anatomic bypass is reserved for gross purulence, psoas or retroperitoneal abscess, or vertebral osteomyelitis.
- CABG is preferred over PCI for coronary artery involvement in Takayasu arteritis, given significantly higher restenosis rates with percutaneous intervention.
- Endovascular repair alone is insufficient for infectious aortitis beyond emergency stabilization; 3-year survival is approximately 20.8% with endovascular repair alone vs. 60.6% with radical open surgery.
- Histopathologic examination of all aortic surgical specimens is essential to identify unsuspected aortitis, found in 2.8–3.8% of thoracic aortic surgeries; the granulomatous or giant cell pattern carries nearly 5-fold higher long-term mortality than the lymphoplasmacytic pattern.
- Statin therapy after aortitis diagnosis may reduce the need for second vascular procedures.
- Lifelong imaging surveillance is required after all aortitis surgery; new vascular lesions develop in up to 47% of patients with isolated aortitis, and 16.1% of CIA patients subsequently develop systemic inflammatory disease.
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Isselbacher EM, Preventza O, Hamilton Black JH 3rd; et al. (2022). "2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease". J Am Coll Cardiol. 80 (24): e223–e393. doi:10.1016/j.jacc.2022.08.004. PMID 36334952 Check
|pmid=value (help). - ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Maz M, Chung SA, Abril A; et al. (2021). "2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis". Arthritis Care Res. 73 (8): 1071–1087. doi:10.1002/acr.24632. PMID 34235871 Check
|pmid=value (help). - ↑ 3.0 3.1 Espitia O, Bruneval P, Assaraf M; et al. (2023). "Long-Term Outcome and Prognosis of Noninfectious Thoracic Aortitis". J Am Coll Cardiol. 82 (11): 1053–1064. doi:10.1016/j.jacc.2023.06.031. PMID 37673506 Check
|pmid=value (help). - ↑ 4.0 4.1 Cacoub P, Vieira M, Langford CA, Tazi Mezalek Z, Saadoun D (2025). "Large-Vessel Vasculitis". Lancet. 406 (10514): 2017–2032. doi:10.1016/S0140-6736(25)01436-9. PMID 40939604 Check
|pmid=value (help). - ↑ Oishi K, Mizuno T, Fujiwara T; et al. (2022). "Surgical Strategy for Inflammatory Thoracic Aortic Aneurysms in the Endovascular Surgery Era". J Vasc Surg. 75 (1): 74–80. doi:10.1016/j.jvs.2021.06.479.
- ↑ Jung JH, Lee YH, Song GG; et al. (2018). "Endovascular Versus Open Surgical Intervention in Patients With Takayasu's Arteritis: A Meta-Analysis". Eur J Vasc Endovasc Surg. 55 (6): 888–899. doi:10.1016/j.ejvs.2018.02.030. PMID 29622513.
- ↑ Espitia O, Bruneval P, Liozon E; et al. (2025). "Histological Pattern of Non-Infectious Thoracic Aortitis Impacts Mortality". J Autoimmun. 151: 103360. doi:10.1016/j.jaut.2025.103360.
- ↑ Kadian-Dodov D, Seo P, Robson PM, Fayad ZA, Olin JW (2022). "Inflammatory Diseases of the Aorta: JACC Focus Seminar, Part 2". J Am Coll Cardiol. 80 (8): 832–844. doi:10.1016/j.jacc.2022.05.046. PMID 35981827 Check
|pmid=value (help). - ↑ 9.0 9.1 9.2 Frisch S, Settembre N, Belkorissat RA; et al. (2025). "Management of Infectious Aortic Aneurysms: Short- And Mid-Term Outcomes". Ann Vasc Surg. 115: 197–205. doi:10.1016/j.avsg.2025.01.042.
- ↑ 10.0 10.1 10.2 10.3 Wilson WR, Bower TC, Creager MA; et al. (2016). "Vascular Graft Infections, Mycotic Aneurysms, and Endovascular Infections: A Scientific Statement From the American Heart Association". Circulation. 134 (20): e412–e460. doi:10.1161/CIR.0000000000000457. PMID 27737955.
- ↑ 11.0 11.1 11.2 Tabiei A, Cifuentes S, Glasgow AE; et al. (2023). "Cryopreserved Arterial Allografts vs Rifampin-Soaked Dacron for the Treatment of Infected Aortic and Iliac Grafts". J Vasc Surg. 78 (4): 1064–1073. doi:10.1016/j.jvs.2023.05.048.